Zottegem, Belgium

Mark A Martens

This inventor holds 1 USPTO granted patent. Top assignee: Continental Pharma Incorporated. Active years: 1987.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 49(Granted Patents)


Company Filing History:


Years Active: 1987

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mark A Martens: Innovator in Glycinamide Derivatives

Introduction

Mark A Martens is a notable inventor based in Zottegem, Belgium. He has made significant contributions to the field of chemistry, particularly in the development of glycinamide derivatives. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing scientific knowledge.

Latest Patents

Mark A Martens holds a patent for "Derivatives of glycinamide, their preparation and their use." This patent describes a glycinamide derivative of the general formula I, where R can be a variety of alkyl, alkenyl, alkynyl, or acyl groups. The versatility of these derivatives highlights their potential applications in various fields, making them a valuable addition to chemical research.

Career Highlights

Throughout his career, Mark has demonstrated a strong commitment to innovation and research. His work at Continental Pharma Incorporated has allowed him to explore new avenues in pharmaceutical chemistry. With a focus on practical applications, he has contributed to the development of compounds that may have significant therapeutic benefits.

Collaborations

Mark A Martens has collaborated with esteemed colleagues such as Alexis H Cordi and Joseph L Roba. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the quality of their research.

Conclusion

Mark A Martens is a distinguished inventor whose work in glycinamide derivatives exemplifies the spirit of innovation in the field of chemistry. His contributions continue to inspire future research and development in pharmaceutical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…